2740747-99-1
Chemical Structure
(S)-EB-FAPI-B2
- CAS No.: 2740747-99-1
- Formula:C78H100N16O22S2
- Molecular Weight:1677.85
InChIKey: UPKLEJRVHWNAEQ-LAHOEMNUSA-N
SMILES: O=S(O)(C1=CC(S(=O)(O)=O)=C(N)C2=C1C=CC(/N=N/C3=C(C=C(C4=CC(C)=C(C=C4)NC([C@H](CCCCNC(CCOCCOCCC(N5CCN(CC5)CCCOC6=CC7=C(N=CC=C7C(NCC(N8[C@@H](CCC8)C#N)=O)=O)C=C6)=O)=O)NC(CN9CCN(CCN(CCN(CC9)CC(O)=O)CC(O)=O)CC(O)=O)=O)=O)C=C3)C)=C2O)=O
Biological Activity: (S)-EB-FAPI-B2 (Compound II-11) is a precursor for radiopharmaceutical labeling, which can be combined with radionuclides to create radionuclide drug conjugates (RDCs). RDCs have the capability to specifically target biomolecules and can be used in medical imaging[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
(S)-EB-FAPI-B2 | (S)-EB-FAPI-B2 (Compound II-11) is a precursor for radiopharmaceutical labeling, which can be combined with radionuclides to create radionuclide drug conjugates (RDCs). RDCs have the capability to specifically target biomolecules and can be used in medical imaging. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Chen XY, et al. Truncated Evans blue modified fibroblast activation protein inhibitor and preparation method and application thereof. CN113582975A. 2021 November 02.
- [2]. Wen X, et al. Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics. Theranostics. 2022 Jan 1;12(1):422-433. [Content Brief]
Keywords
